Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2015

01-07-2015 | Review

Protective and detrimental roles of inflammasomes in disease

Authors: Pedro H. V. Saavedra, Dieter Demon, Hanne Van Gorp, Mohamed Lamkanfi

Published in: Seminars in Immunopathology | Issue 4/2015

Login to get access

Abstract

Over recent years, inflammasomes have emerged as key regulators of immune and inflammatory responses. They induce programmed cell death and direct the release of danger signals and the inflammatory cytokines interleukin (IL)-1β and IL-18. The concerted actions of inflammasomes are of utmost importance for responding adequately to harmful environmental agents and infections. However, deregulated inflammasome signaling is increasingly linked to a diversity of human pathologies, including rheumatoid arthritis, inflammatory bowel disease, and rare, hereditary periodic fever syndromes. In this review, we discuss recent insight in the protective and detrimental roles of inflammasomes in selected infectious, autoinflammatory and autoimmune diseases, and cover clinically approved therapies that interfere with inflammasome signaling. These findings highlight the importance of fine-balancing the Ying and Yang activities of inflammasomes for sustained homeostasis and suggest that further understanding of inflammasome mechanisms may offer new cures for human diseases.
Literature
1.
Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161PubMed
2.
Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820PubMed
3.
Broz P, von Moltke J, Jones JW, Vance RE, Monack DM (2010) Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 8:471–483PubMedCentralPubMed
4.
Van Opdenbosch N, Gurung P, Vande Walle L, Fossoul A, Kanneganti TD, Lamkanfi M (2014) Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun 5:3209PubMedCentralPubMed
5.
Lamkanfi M, Dixit VM (2014) Mechanisms and functions of inflammasomes. Cell 157:1013–1022PubMed
6.
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550PubMed
7.
Lamkanfi M (2011) Emerging inflammasome effector mechanisms. Nat Rev Immunol 11:213–220PubMed
8.
Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M (2014) Inflammasomes in respiratory disease: from bench to bedside. Chest 145:1121–1133PubMed
9.
Clay GM, Sutterwala FS, Wilson ME (2014) NLR proteins and parasitic disease. Immunol Res 59:142–152PubMed
10.
11.
Chen I, Ichinohe T (2015) Response of host inflammasomes to viral infection. Trends Microbiol 23:55–63PubMed
12.
Franchi L, Munoz-Planillo R, Nunez G (2012) Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13:325–332PubMedCentralPubMed
13.
Bauernfeind F, Hornung V (2013) Of inflammasomes and pathogens—sensing of microbes by the inflammasome. EMBO Mol Med 5:814–826PubMedCentralPubMed
14.
Tian X, Pascal G, Monget P (2009) Evolution and functional divergence of NLRP genes in mammalian reproductive systems. BMC Evol Biol 9:202PubMedCentralPubMed
15.
Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38:240–244PubMed
16.
Sastalla I, Crown D, Masters SL, McKenzie A, Leppla SH, Moayeri M (2013) Transcriptional analysis of the three Nlrp1 paralogs in mice. BMC Genomics 14:188PubMedCentralPubMed
17.
Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O’Donnell JA et al (2012) NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37:1009–1023PubMedCentralPubMed
18.
Moayeri M, Crown D, Newman ZL, Okugawa S, Eckhaus M, Cataisson C et al (2010) Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog 6:e1001222PubMedCentralPubMed
19.
Terra JK, Cote CK, France B, Jenkins AL, Bozue JA, Welkos SL et al (2010) Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol 184:17–20PubMedCentralPubMed
20.
Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462:199–204PubMed
21.
Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD et al (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734–737PubMed
22.
Chavarria-Smith J, Vance RE (2013) Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog 9:e1003452PubMedCentralPubMed
23.
Hett EC, Slater LH, Mark KG, Kawate T, Monks BG, Stutz A et al (2013) Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat Chem Biol 9:398–405PubMed
24.
Guey B, Bodnar M, Manie SN, Tardivel A, Petrilli V (2014) Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci U S A 111:17254–17259PubMedCentralPubMed
25.
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P et al (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514:187–192PubMed
26.
Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J et al (2011) Non-canonical inflammasome activation targets caspase-11. Nature 479:117–121PubMed
27.
Broz P, Ruby T, Belhocine K, Bouley DM, Kayagaki N, Dixit VM et al (2012) Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490:288–291PubMedCentralPubMed
28.
Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S et al (2013) Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341:1246–1249PubMed
29.
Knodler LA, Crowley SM, Sham HP, Yang H, Wrande M, Ma C et al (2014) Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe 16:249–256PubMed
30.
Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE et al (2013) Caspase-11 protects against bacteria that escape the vacuole. Science 339:975–978PubMedCentralPubMed
31.
Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA (2013) Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341:1250–1253PubMedCentralPubMed
32.
Demon D, Vande Walle L, Lamkanfi M (2014) Sensing the enemy within: how macrophages detect intracellular gram-negative bacteria. Trends Biochem Sci 39:574–576PubMedCentralPubMed
33.
Lage SL, Longo C, Branco LM, da Costa TB, Buzzo Cde L, Bortoluci KR (2014) Emerging concepts about NAIP/NLRC4 inflammasomes. Front Immunol 5:309PubMedCentralPubMed
34.
Rayamajhi M, Zak DE, Chavarria-Smith J, Vance RE, Miao EA (2013) Cutting edge: mouse NAIP1 detects the type III secretion system needle protein. J Immunol 191:3986–3989PubMed
35.
Yang J, Zhao Y, Shi J, Shao F (2013) Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A 110:14408–14413PubMedCentralPubMed
36.
Kofoed EM, Vance RE (2011) Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477:592–595PubMedCentralPubMed
37.
Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H et al (2011) The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596–600PubMed
38.
Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M et al (2012) Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 490:539–542PubMed
39.
Matusiak M, Van Opdenbosch N, Vande Walle L, Sirard JC, Kanneganti TD, Lamkanfi M (2015) Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5. Proc Natl Acad Sci U S A 112:1541–1546PubMedCentralPubMed
40.
Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A et al (2010) Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 11:1136–1142PubMedCentralPubMed
41.
Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F (2011) Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1beta is deleterious. PLoS Pathog 7:e1002452PubMedCentralPubMed
42.
Warren SE, Armstrong A, Hamilton MK, Mao DP, Leaf IA, Miao EA et al (2010) Cutting edge: cytosolic bacterial DNA activates the inflammasome via Aim2. J Immunol 185:818–821PubMedCentralPubMed
43.
Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L et al (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11:395–402PubMedCentralPubMed
44.
Wu J, Fernandes-Alnemri T, Alnemri ES (2010) Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J Clin Immunol 30:693–702PubMedCentralPubMed
45.
Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA (2010) Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe 7:412–419PubMedCentralPubMed
46.
Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J et al (2010) The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 11:385–393PubMedCentralPubMed
47.
Xu H, Yang J, Gao W, Li L, Li P, Zhang L et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513:237–241PubMed
48.
Gavrilin MA, Abdelaziz DH, Mostafa M, Abdulrahman BA, Grandhi J, Akhter A et al (2012) Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 188:3469–3477PubMedCentralPubMed
49.
Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) The hereditary autoinflammatory disorders uncovered. Autoimmun Rev 13:892–900PubMed
50.
Broderick L, De Nardo D, Franklin BS, Hoffman HM, Latz E (2015) The inflammasomes and autoinflammatory syndromes. Annu Rev Pathol 10:395–424PubMed
51.
Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668PubMedCentralPubMed
52.
Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34:755–768PubMedCentralPubMed
53.
Roldan R, Ruiz AM, Miranda MD, Collantes E (2008) Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine Rev Rhum 75:504–505
54.
Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–271PubMed
55.
Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33:1–9PubMed
56.
Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615–620PubMedCentralPubMed
57.
Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46:2445–2452PubMed
58.
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581–592PubMedCentralPubMed
59.
Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443–2452PubMed
60.
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416–2425PubMed
61.
Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860–874PubMedCentralPubMed
62.
Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C et al (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875–887PubMedCentralPubMed
63.
Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM (2013) Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 123:4695–4705PubMedCentralPubMed
64.
Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D et al (2012) Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One 7:e35979PubMedCentralPubMed
65.
Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375–2386PubMedCentralPubMed
66.
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146PubMedCentralPubMed
67.
Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M et al (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46:1135–1139PubMedCentralPubMed
68.
Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K (2014) An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211:2385–2396PubMedCentralPubMed
69.
Hu Z, Yan C, Liu P, Huang Z, Ma R, Zhang C et al (2013) Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science 341:172–175PubMed
70.
Luksch H, Romanowski MJ, Chara O, Tungler V, Caffarena ER, Heymann MC et al (2013) Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1beta. Hum Mutat 34:122–131PubMed
71.
Lamkanfi M, Kalai M, Saelens X, Declercq W, Vandenabeele P (2004) Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem 279:24785–24793PubMed
72.
Heymann MC, Winkler S, Luksch H, Flecks S, Franke M, Russ S et al (2014) Human procaspase-1 variants with decreased enzymatic activity are associated with febrile episodes and may contribute to inflammation via RIP2 and NF-kappaB signaling. J Immunol 192:4379–4385PubMed
73.
Olson JK, Miller SD (2009) The innate immune response affects the development of the autoimmune response in Theiler’s virus-induced demyelinating disease. J Immunol 182:5712–5722PubMedCentralPubMed
74.
75.
Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C et al (2009) Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat Genet 41:71–76PubMedCentralPubMed
76.
Tamura K, Fukuda Y, Sashio H, Takeda N, Bamba H, Kosaka T et al (2002) IL18 polymorphism is associated with an increased risk of Crohn’s disease. J Gastroenterol 37:111–116PubMed
77.
Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB et al (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207:1045–1056PubMedCentralPubMed
78.
Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD (2010) The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32:379–391PubMedCentralPubMed
79.
Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y et al (2011) NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17:1359–1372PubMedCentralPubMed
80.
Lebeis SL, Powell KR, Merlin D, Sherman MA, Kalman D (2009) Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 77:604–614PubMedCentralPubMed
81.
Takagi H, Kanai T, Okazawa A, Kishi Y, Sato T, Takaishi H et al (2003) Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 38:837–844PubMed
82.
Carvalho FA, Nalbantoglu I, Aitken JD, Uchiyama R, Su Y, Doho GH et al (2012) Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol 5:288–298PubMedCentralPubMed
83.
Demon D, Kuchmiy A, Fossoul A, Zhu Q, Kanneganti TD, Lamkanfi M (2014) Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol 7:1480–1491PubMedCentralPubMed
84.
Williams TM, Leeth RA, Rothschild DE, McDaniel DK, Coutermarsh-Ott SL, Simmons AE et al (2015) Caspase-11 attenuates gastrointestinal inflammation and experimental colitis pathogenesis. Am J Physiol Gastrointest Liver Physiol 308:G139–150PubMed
85.
Oficjalska K, Raverdeau M, Aviello G, Wade SC, Hickey A, Sheehan KM et al (2015) Protective role for caspase-11 during acute experimental murine colitis. J Immunol 194:1252–1260PubMedCentralPubMed
86.
Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–292PubMed
87.
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32PubMed
88.
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC (2014) Biologics in Rheumatoid Arthritis G, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73:1202–1210PubMed
89.
Yang CA, Huang ST, Chiang BL (2014) Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population. Scand J Rheumatol 43:146–152PubMed
90.
Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev CD005121
91.
Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P et al (2014) Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512:69–73PubMed
92.
Pontillo A, Brandao L, Guimaraes R, Segat L, Araujo J, Crovella S (2010) Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43:583–589PubMed
93.
Pontillo A, Girardelli M, Kamada AJ, Pancotto JA, Donadi EA, Crovella S et al (2012) Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 45:271–278PubMed
94.
Kahlenberg JM, Kaplan MJ (2014) The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol 26:475–481PubMed
95.
Magitta NF, Boe Wolff AS, Johansson S, Skinningsrud B, Lie BA, Myhr KM et al (2009) A coding polymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes Immun 10:120–124PubMed
96.
Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S (2013) AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol 33:925–937PubMed
97.
Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y et al (2013) NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A 110:2952–2956PubMedCentralPubMed
98.
Jin Y, Birlea SA, Fain PR, Spritz RA (2007) Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 127:2558–2562PubMed
99.
Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216–1225PubMed
100.
Zurawek M, Fichna M, Januszkiewicz-Lewandowska D, Gryczynska M, Fichna P, Nowak J (2010) A coding variant in NLRP1 is associated with autoimmune Addison’s disease. Hum Immunol 71:530–534PubMed
101.
Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64:630–633PubMedCentralPubMed
102.
Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F (2005) Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 4:542–548PubMed
103.
Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, Iwakura Y et al (2006) IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 17:109–116PubMed
104.
Kahlenberg JM, Yalavarthi S, Zhao W, Hodgin JB, Reed TJ, Tsuji NM et al (2014) An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheum 66:152–162
105.
Lech M, Lorenz G, Kulkarni OP, Grosser MO, Stigrot N, Darisipudi MN et al (2014) NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-beta receptor signalling. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2014-205496 PubMed
106.
Aksentijevich I, DP C, Remmers EF, Mueller JL, Le J, Kolodner RD et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56:1273–1285PubMedCentralPubMed
107.
Neven B, Prieur AM, Quartier dit Maire P (2008) Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4:481–489PubMed
108.
Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D et al (2014) Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford) 53:665–670
109.
Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779–1785PubMedCentralPubMed
110.
Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34:2091–2103PubMed
111.
de Koning HD, van Gijn ME, Stoffels M, Jongekrijg J, Zeeuwen PL, Elferink MG et al (2014) Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. doi:10.​1016/​j.​jaci.​2014.​07.​050 PubMed
112.
113.
Dwivedi M, Laddha NC, Mansuri MS, Marfatia YS, Begum R (2013) Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Br J Dermatol 169:1114–1125PubMed
114.
Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B et al (2014) Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol 170:816–823PubMed
115.
Alkhateeb A, Jarun Y, Tashtoush R (2013) Polymorphisms in NLRP1 gene and susceptibility to autoimmune thyroid disease. Autoimmunity 46:215–221PubMed
116.
Grishman EK, White PC, Savani RC (2012) Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes. Pediatr Res 71:626–632PubMed
117.
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905–1915PubMed
118.
Schott WH, Haskell BD, Tse HM, Milton MJ, Piganelli JD, Choisy-Rossi CM et al (2004) Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 53:99–104PubMed
119.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM et al (2010) Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32:367–378PubMed
120.
Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Soderkvist P (2008) Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology 47:415–417PubMed
121.
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S et al (2014) Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73:1202–1210PubMed
122.
123.
Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 43:908–912PubMed
124.
Kimkong I, Avihingsanon Y, Hirankarn N (2009) Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus 18:1066–1072PubMed
Metadata
Title
Protective and detrimental roles of inflammasomes in disease
Authors
Pedro H. V. Saavedra
Dieter Demon
Hanne Van Gorp
Mohamed Lamkanfi
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2015
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-015-0485-5

Other articles of this Issue 4/2015

Seminars in Immunopathology 4/2015 Go to the issue

Review

Update on genetics and pathogenesis of autoinflammatory diseases: the last 2 years

Review

Type I interferonopathies—an expanding disease spectrum of immunodysregulation

Review

New monogenic autoinflammatory diseases—a clinical overview

Review

CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease

Review

Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?

Review

New discoveries in CRMO: IL-1β, the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits